Company / EPS (Diluted)
GYRE THERAPEUTICS, INC. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.05
FY2025
5-year range
-$2.93 / $0.05
FY2021-FY2025
Trend
+103.5%
vs FY2024
Sector context
#46 of 204
Health Care
What the data says
GYRE THERAPEUTICS, INC.'s eps (diluted) of $0.05 is higher than 77% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 8 years, ranging from $-7.45 in FY2018 to $0.05 in FY2025.
Based on SEC 10-K filings.
0.05 in FY2025 with a 3-year CAGR of +18.6%. Top quartile in the Health Care sector.
Improved from $0.03 to $0.05 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +18.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 204This company $0.05 Sector average -$0.98
▼
+105.1% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 103.5% year-over-year.
- Ranks #46 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.05 | +103.5% |
| FY2024 | -$1.41 | -4800.0% |
| FY2023 | $0.03 | +0.0% |
| FY2022 | $0.03 | +101.0% |
| FY2021 | -$2.93 | +36.3% |
| FY2020 | -$4.60 | -71.6% |
| FY2019 | -$2.68 | +64.0% |
| FY2018 | -$7.45 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026